Full title: The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Author/creator: Song, Meng‐Jia, Pan, Qiu‐Zhong, Ding, Ya, Zeng, Jianxiong, Dong, Pei, Zhao, Jing‐Jing, Tang, Yan, Li, Jingjing, Zhang, Zhiling, He, Junyi, Yang, Jieying, Huang, Yue, Peng, Ruiqing, Wang, Qi‐Jing, Gu, Jia‐Mei, He, Jia, Li, Yong‐Qiang, Chen, Shi‐Ping, Huang, Rongxing, Zhou, Zi‐Qi, Yang, Chaopin, Han, Yulong, Chen, Hao, Liu, Heping, Xia, Shangzhou, Wan, Yang, Weng, De‐Sheng, Xia, Liming, Zhou, Fang‐Jian, Xia, Jian‐Chuan.

Call Numbers:

Record Identifier: TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f

Language: English

Formats: Articles

Publishers: Australia: John Wiley & Sons, Inc

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_207802f67c564291ab3647874de5462f